Clinical trials: Reduced Vision
Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM)
Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia
This study was designed to evaluate the efficacy and safety of two different dosing regimens of 0.5 mg ranibizumab given as intravitreal injection in comparison to verteporfin PDT in patients with visual impairment due to…
- Trial name
- Brilliance (NCT01922102)
- Testing
- Ranibizumab 0.5mg, Ranibizumab 0.5 mg, Verteporfin PDT
- Where
- 47 sites in China, Hong Kong and 4 more
- Volunteers
- 457 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema
Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema
This study was designed to confirm the efficacy and safety of ranibizumab (0.5 mg) as adjunctive therapy when added to laser photocoagulation and/or as monotherapy in Asian patients with visual impairment due to Diabetic Macular…
- Trial name
- REVEAL (NCT00989989)
- Testing
- Ranibizumab, Laser photocoagulation
- Where
- 35 sites in China, Hong Kong and 4 more
- Volunteers
- 396 people
- Sponsor
- Novartis
Glaucoma, Open-Angle, Ocular Hypertension
Phase 1-2 Evaluation of OT-730 Eye Drops in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-Angle Glaucoma
The purpose of this study is to evaluate the safety and potential efficacy of a new drug, OT-730 ophthalmic solution (eye drops), in reducing intraocular pressure in the eyes of patients with open angle glaucoma or ocular…
- Trial name
- NCT00753168
- Testing
- OT-730 ophthalmic solution, timolol maleate ophthalmic solution
- Where
- 5 sites in United States
- Volunteers
- 48 people
- Sponsor
- Othera Pharmaceuticals
Primary Open-angle Glaucoma
PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM)
Objectives: To evaluate the non-inferiority in the intraocular pressure decrease of the preservative-free ophthalmic solution PRO-122, manufactured by Laboratorios Sophia S.A.
- Trial name
- PRO-122LATAM (NCT03193333)
- Testing
- PRO-122, Timolol eye drops, Dorzolamide-Timolol Ophthalmic
- Where
- 2 sites in Colombia, Mexico
- Volunteers
- 51 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Choroidal Neovascularization (CNV)
Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization.
This study was conducted to evaluate the efficacy and safety of 0.5 mg ranibizumab in adult and adolescent patients with visual impairment due to choridal neovascularization (CNV).
- Trial name
- NCT01840410
- Testing
- Ranibizumab
- Where
- 59 sites in Australia, Canada and 19 more
- Volunteers
- 183 people
- Sponsor
- Novartis Pharmaceuticals
Primary Open-Angle Glaucoma (POAG)
GVB-2001 Gene Therapy Via Intracameral Injection for the Treatment of Primary Open Angle Glaucoma
This is an investigator initiated, single center, open label, non-randomized, exploratory clinical study. The purpose is to assess the safety and preliminary efficacy of gene therapy GVB-2001 (ScAAV2-dnRhoA) delivered via…
- Trial name
- NCT06921317
- Testing
- GVB-2001-high dose, GVB-2001-low dose
- Where
- China
- Volunteers
- 6 people
- Sponsor
- IVIEW Therapeutics Inc.
Diabetic Macula Edema
Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
The purpose of this study is to evaluate the efficacy and safety of brolucizumab in treatment of patients with visual impairment due to diabetic macular edema (DME).
- Trial name
- BUZZARD (NCT04079231)
- Testing
- Brolucizumab, Aflibercept
- Sponsor
- Novartis Pharmaceuticals
Mesopic Vision, Night Vision Loss
Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances
Safety and efficacy of 0.75% Phentolamine Ophthalmic Solution to improve mesopic low contrast visual acuity in subjects with post-refractive surgery visual disturbances.
- Trial name
- LYNX-2 (NCT06349759)
- Testing
- phentolamine ophthalmic solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist
- Where
- 25 sites in United States
- Volunteers
- 200 people
- Sponsor
- Opus Genetics, Inc
Neovascular AMD, Visual Impairment Due to DME, Visual Impairment Due to Macular Oedema Secondary to Branch or Central RVO, Visual Impairment Due to CNV
Observation of Treatment Patterns With Lucentis in Approved Indications
A multicentre, open-label, non-interventional study to observe treatment patterns in patients with wet age-related macular degeneration (wAMD), with visual impairment due to diabetic macular edema (DME), due to macular edema…
- Trial name
- OCEAN (NCT02194803)
- Where
- Germany
- Volunteers
- 5,778 people
- Sponsor
- Novartis Pharmaceuticals
Primary Open Angle Glaucoma
Clinical Study Evaluating the Safety and Performance of the MIST Device for Intraocular Pressure Reduction in Patients With Primary Open-Angle Glaucoma
It is an interventional study for the treatment of Primary Open-Angle Glaucoma (POAG) using the Hexiris Microinvasive Scleral Trephine (MIST) system. This medical device includes a sclerectomy punch and injector assembly.
- Trial name
- NCT07358650
- Testing
- Hexiris Microinvasive Scleral Trephine (MIST)
- Where
- 5 sites in Canada
- Volunteers
- 25 people
- Sponsor
- Hexiris Inc
Open-angle Glaucoma, Cataract
Efficacy and Safety of Trabecular Meshwork Microstent Drainage System ( MicroCOGO )
It is a prospective, multicenter, randomized, open label, parallel controlled, superiority clinical trial that evaluate efficacy and safety of Trabecular Meshwork Microstent Drainage System in Reducing Intraocular Pressure in…
- Trial name
- MicroCOGO (NCT06741774)
- Testing
- Trabecular Meshwork Microstent Drainage System, phacoemulsification
- Where
- China
- Volunteers
- 207 people
- Sponsor
- Healthguard Biomed
Central Retinal Vein Occlusion
Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO)
Provide efficacy and safety data on intravitreal injections of ranibizumab 0.5 mg in patients with visual impairment due to macular edema secondary to CRVO
- Trial name
- Camellia (NCT01976312)
- Testing
- Ranibizumab 0.5 mg
- Where
- 34 sites in China, Hong Kong and 5 more
- Volunteers
- 252 people
- Sponsor
- Novartis Pharmaceuticals
Blindness and Low Vision
A Pilot Study Comparing Performance of Blind Participants on 12 Tasks, With and Without the ARIA Device
Summary The environment in which we live, play and travel is primarily built by and for people with sight. Navigating the sighted world with blindness can be exhausting, as it involves disorientation, social isolation, increased…
- Trial name
- NCT06477809
- Testing
- ARIA Glasses ( Augmented Reality in Audio )
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- ARIA Research Pty Ltd
Decrease in Night Vision, Disturbance; Vision, Loss
Single Dose Study of Phentolamine Mesylate Eye Drops in Patients With Severe Night Vision Disturbances
The objectives of this study are: To assess the effect of ophthalmic phentolamine mesylate in mesopic conditions on the four endpoints: 1. Contrast sensitivity 2. Low contrast visual acuity 3. Wavefront aberrometry 4.
- Trial name
- SNV (NCT04004507)
- Testing
- Phentolamine Mesylate Ophthalmic Solution 1%
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Opus Genetics, Inc
Age Related Macular Degeneration
Study of WA-NG Telescope Prosthesis in Patients With End-stage Age-related Macular Degeneration
This is a pilot study to evaluate the safety of the Model WA-NG telescope prosthesis in patients with bilateral moderate to profound central vision impairment due to end-stage age-related macular degeneration.
- Trial name
- NCT01731964
- Testing
- Telescope prosthesis, WA-NG Telescope Prothesis
- Where
- Israel
- Sponsor
- VisionCare, Inc.
Primary Open Angle Glaucoma (POAG)
Direct Selective Laser Trabeculoplasty (DSLT) for Reducing Eye Pressure in Non-Caucasian Patients With Open Angle Glaucoma
The goal of this clinical trial is to to evaluate how well Direct Selective Laser Trabeculoplasty (DSLT) lowers eye pressure in eyes of adult, non-Caucasian participants with primary open angle glaucoma.
- Trial name
- NCT07147647
- Testing
- Direct Selective Laser Trabeculoplasty
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Select Eye Care